Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALPL | P05186 | 1/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | ALPG | P10696 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10903296 | 0.85 | KMT2A (0.67) | KMT2AMEN1ALPLALPIALPG | |
| SCHEMBL404889 | 0.84 | KMT2A (0.54) | KMT2AMEN1HDAC1HDAC2GAA | |
| SCHEMBL27997601 | 0.84 | KMT2A (0.54) | KMT2AMEN1HDAC1HDAC2GAA | |
| SCHEMBL2858346 | 0.82 | PKM (0.63) | KMT2AMEN1ALPLALPIALPG | |
| SCHEMBL11058212 | 0.82 | KMT2A (0.62) | KMT2AMEN1ALPLALPIALPG | |
| SCHEMBL8290704 | 0.82 | ALDH1A1 (0.61) | KMT2AMEN1ALPL | |
| SCHEMBL3623600 | 0.82 | KMT2A (0.62) | KMT2AMEN1ALPLALPIALPG | |
| SCHEMBL14336397 | 0.82 | GAA (0.64) | KMT2AMEN1ALPLALPIALPG | |
| SCHEMBL1272486 | 0.82 | ALDH1A1 (0.73) | KMT2AMEN1ALPLALPIALPG | |
| SCHEMBL5487993 | 0.81 | NR4A2 (0.58) | KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115707691-A | Phenoxymethyl-1,4,2-dioxazole-5-ketone and preparation method thereof | 张家港市国泰华荣化工新材料有限公司 | 2023-02-21 | — | — | CN | claimed |
| EP-0575556-A4 | PALYTOXIN-RELATED PRODRUGS AND A METHOD FOR THEIR ADMINISTRATION. | HAWAII BIOTECH GROUP (US) | 1994-03-21 | — | — | EP | claimed |
| EP-0575556-A1 | PALYTOXIN-RELATED PRODRUGS AND A METHOD FOR THEIR ADMINISTRATION | HAWAII BIOTECHNOLOGY GROUP, INC. (US) | 1993-12-29 | — | — | EP | claimed |
| WO-1992016203-A1 | PALYTOXIN-RELATED PRODRUGS AND A METHOD FOR THEIR ADMINISTRATION | HAWAII BIOTECHNOLOGY GROUP, INC. (US) | 1992-10-01 | — | — | WO | claimed |
| CN-115160097-B | Method for synthesizing amide by reducing N-O bond by thioacetic acid | 温州大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-115707691-A | Phenoxymethyl-1,4,2-dioxazole-5-ketone and preparation method thereof | 张家港市国泰华荣化工新材料有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-115707691-A | Phenoxymethyl-1,4,2-dioxazole-5-ketone and preparation method thereof | 张家港市国泰华荣化工新材料有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-115160097-A | Method for reducing N-O bonding into amide by thioacetic acid | 温州大学 | 2022-10-11 | — | — | CN | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-8728470-B2 | CAB molecules | DANISCO US INC. (US) | 2014-05-20 | — | — | US | disclosed |
| WO-1997002349-A1 | PHENYLACETYL-CoA LIGASE FROM PENICILLIUM CHRYSOGENUM | SMITHKLINE BEECHAM PLC (GB) | 1997-01-23 | — | — | WO | disclosed |
| EP-0302473-B1 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | BRISTOL MYERS SQUIBB CO (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0575556-A4 | PALYTOXIN-RELATED PRODRUGS AND A METHOD FOR THEIR ADMINISTRATION. | HAWAII BIOTECH GROUP (US) | 1994-03-21 | — | — | EP | disclosed |
| EP-0575556-A1 | PALYTOXIN-RELATED PRODRUGS AND A METHOD FOR THEIR ADMINISTRATION | HAWAII BIOTECHNOLOGY GROUP, INC. (US) | 1993-12-29 | — | — | EP | disclosed |
| EP-0540859-A1 | Anthracycline prodrugs | Bristol-Myers Squibb Company (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992016203-A1 | PALYTOXIN-RELATED PRODRUGS AND A METHOD FOR THEIR ADMINISTRATION | HAWAII BIOTECHNOLOGY GROUP, INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4975278-A | Converting the prodrug at the tumor site to the active drug by means of the conjugate bound to a tumor surface antigen | BRISTOL-MYERS COMPANY (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0302473-A2 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | Bristol-Myers Squibb Company (US) | 1989-02-08 | — | — | EP | disclosed |